Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:38 PM
Study NCT ID:
NCT04436640
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-21
First Post:
2020-06-15
Brief Title:
A Study to Evaluate the Long-term Safety Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Open-Label Extension Study to Asses the Long-Term Safety Tolerability and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BE MOVING
Brief Summary:
The purpose of the study is to demonstrate the long-term safety tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis axSpA also known as radiographic axSpa r-axSpA including ankylosing spondylitis AS and nonradiographic axial spondyloarthritis nr-axSpa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-004163-47 | EUDRACT_NUMBER | None | None |